Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation

Abstract Phospholipids occurring in cell membranes and lipoproteins are converted into oxidized phospholipids (OxPL) by oxidative stress promoting atherosclerotic plaque formation. Here, OxPL were characterized as novel targets in acute and chronic inflammatory pain. Oxidized 1-palmitoyl-2-arachidon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beatrice Oehler, Katrin Kistner, Corinna Martin, Jürgen Schiller, Rafaela Mayer, Milad Mohammadi, Reine-Solange Sauer, Milos R. Filipovic, Francisco R. Nieto, Jan Kloka, Diana Pflücke, Kerstin Hill, Michael Schaefer, Marzia Malcangio, Peter W. Reeh, Alexander Brack, Robert Blum, Heike L. Rittner
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a6c20966bd864799baf52d5a980c648e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6c20966bd864799baf52d5a980c648e
record_format	dspace
spelling	oai:doaj.org-article:a6c20966bd864799baf52d5a980c648e2021-12-02T15:04:52ZInflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation10.1038/s41598-017-05348-32045-2322https://doaj.org/article/a6c20966bd864799baf52d5a980c648e2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05348-3https://doaj.org/toc/2045-2322Abstract Phospholipids occurring in cell membranes and lipoproteins are converted into oxidized phospholipids (OxPL) by oxidative stress promoting atherosclerotic plaque formation. Here, OxPL were characterized as novel targets in acute and chronic inflammatory pain. Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) and its derivatives were identified in inflamed tissue by mass spectrometry and binding assays. They elicited calcium influx, hyperalgesia and induced pro-nociceptive peptide release. Genetic, pharmacological and mass spectrometric evidence in vivo as well as in vitro confirmed the role of transient receptor potential channels (TRPA1 and TRPV1) as OxPAPC targets. Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimetic peptide D-4F, capturing OxPAPC in atherosclerosis, prevented inflammatory hyperalgesia, and in vitro TRPA1 activation. Administration of D-4F or E06 to rats profoundly ameliorated mechanical hyperalgesia and inflammation in collagen-induced arthritis. These data reveal a clinically relevant role for OxPAPC in inflammation offering therapy for acute and chronic inflammatory pain treatment by scavenging OxPAPC.Beatrice OehlerKatrin KistnerCorinna MartinJürgen SchillerRafaela MayerMilad MohammadiReine-Solange SauerMilos R. FilipovicFrancisco R. NietoJan KlokaDiana PflückeKerstin HillMichael SchaeferMarzia MalcangioPeter W. ReehAlexander BrackRobert BlumHeike L. RittnerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-22 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Beatrice Oehler Katrin Kistner Corinna Martin Jürgen Schiller Rafaela Mayer Milad Mohammadi Reine-Solange Sauer Milos R. Filipovic Francisco R. Nieto Jan Kloka Diana Pflücke Kerstin Hill Michael Schaefer Marzia Malcangio Peter W. Reeh Alexander Brack Robert Blum Heike L. Rittner Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
description	Abstract Phospholipids occurring in cell membranes and lipoproteins are converted into oxidized phospholipids (OxPL) by oxidative stress promoting atherosclerotic plaque formation. Here, OxPL were characterized as novel targets in acute and chronic inflammatory pain. Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) and its derivatives were identified in inflamed tissue by mass spectrometry and binding assays. They elicited calcium influx, hyperalgesia and induced pro-nociceptive peptide release. Genetic, pharmacological and mass spectrometric evidence in vivo as well as in vitro confirmed the role of transient receptor potential channels (TRPA1 and TRPV1) as OxPAPC targets. Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimetic peptide D-4F, capturing OxPAPC in atherosclerosis, prevented inflammatory hyperalgesia, and in vitro TRPA1 activation. Administration of D-4F or E06 to rats profoundly ameliorated mechanical hyperalgesia and inflammation in collagen-induced arthritis. These data reveal a clinically relevant role for OxPAPC in inflammation offering therapy for acute and chronic inflammatory pain treatment by scavenging OxPAPC.
format	article
author	Beatrice Oehler Katrin Kistner Corinna Martin Jürgen Schiller Rafaela Mayer Milad Mohammadi Reine-Solange Sauer Milos R. Filipovic Francisco R. Nieto Jan Kloka Diana Pflücke Kerstin Hill Michael Schaefer Marzia Malcangio Peter W. Reeh Alexander Brack Robert Blum Heike L. Rittner
author_facet	Beatrice Oehler Katrin Kistner Corinna Martin Jürgen Schiller Rafaela Mayer Milad Mohammadi Reine-Solange Sauer Milos R. Filipovic Francisco R. Nieto Jan Kloka Diana Pflücke Kerstin Hill Michael Schaefer Marzia Malcangio Peter W. Reeh Alexander Brack Robert Blum Heike L. Rittner
author_sort	Beatrice Oehler
title	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
title_short	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
title_full	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
title_fullStr	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
title_full_unstemmed	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
title_sort	inflammatory pain control by blocking oxidized phospholipid-mediated trp channel activation
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a6c20966bd864799baf52d5a980c648e
work_keys_str_mv	AT beatriceoehler inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT katrinkistner inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT corinnamartin inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT jurgenschiller inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT rafaelamayer inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT miladmohammadi inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT reinesolangesauer inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT milosrfilipovic inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT franciscornieto inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT jankloka inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT dianapflucke inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT kerstinhill inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT michaelschaefer inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT marziamalcangio inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT peterwreeh inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT alexanderbrack inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT robertblum inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation AT heikelrittner inflammatorypaincontrolbyblockingoxidizedphospholipidmediatedtrpchannelactivation
_version_	1718389033595305984

Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation

Ejemplares similares